.

Deeper Knowledge, Faster

  • Find suppliers and generic API sources
  • Predict branded drug patent expiration
  • Drug patents and clinical trials in dozens of countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Colorcon
Fish and Richardson
Cantor Fitzgerald
Julphar
Boehringer Ingelheim
Chinese Patent Office
US Department of Justice
McKesson
Baxter
Express Scripts

Generated: June 24, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 022505

« Back to Dashboard
NDA 022505 describes EGRIFTA, which is a drug marketed by Theratechnologies and is included in one NDA. It is available from two suppliers. There are three patents protecting this drug. Additional details are available on the EGRIFTA profile page.

The generic ingredient in EGRIFTA is tesamorelin acetate. Two suppliers are listed for this compound. Additional details are available on the tesamorelin acetate profile page.

Summary for NDA: 022505

Tradename:
1
Applicant:
1
Ingredient:
1
Patents:1

Suppliers and Packaging for NDA: 022505

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
EGRIFTA
tesamorelin acetate
POWDER;SUBCUTANEOUS 022505 NDA EMD Serono, Inc. 44087-2011 44087-2011-2 1 KIT in 1 BOX (44087-2011-2) * 2 mL in 1 VIAL * 10 mL in 1 BOTTLE (0409-4887-34)
EGRIFTA
tesamorelin acetate
POWDER;SUBCUTANEOUS 022505 NDA Theratechnologies Inc. 62064-011 62064-011-60 1 KIT in 1 BOX (62064-011-60) * 1 mL in 1 VIAL * 30 BOTTLE in 1 TRAY (0409-4887-34) > 10 mL in 1 BOTTLE

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:POWDER;SUBCUTANEOUSStrengthEQ 1MG BASE/VIAL
Approval Date:Nov 10, 2010TE:RLD:Yes
Patent:5,861,379Patent Expiration:May 26, 2020Product Flag?YSubstance Flag?YDelist Request?
Patented Use:REDUCTION OF EXCESS ABDOMINAL FAT IN HIV-INFECTED PATIENTS WITH LIPODYSTROPHY
Patent:7,144,577Patent Expiration:Jul 14, 2020Product Flag?Substance Flag?Delist Request?
Patented Use:REDUCTION OF EXCESS ABDOMINAL FAT IN HIV-INFECTED PATIENTS WITH LIPODYSTROPHY
Patent:7,316,997Patent Expiration:Aug 14, 2023Product Flag?Substance Flag?Delist Request?
Patented Use:REDUCTION OF EXCESS ABDOMINAL FAT IN HIV-INFECTED PATIENTS WITH LIPODYSTROPHY

Expired Orange Book Patents for NDA: 022505

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Theratechnologies
EGRIFTA
tesamorelin acetate
POWDER;SUBCUTANEOUS022505-002Nov 29, 20116,020,311► Subscribe
Theratechnologies
EGRIFTA
tesamorelin acetate
POWDER;SUBCUTANEOUS022505-001Nov 10, 20106,020,311► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.



Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Chinese Patent Office
Teva
Covington
Baxter
Dow
UBS
Fuji
Harvard Business School
US Army
QuintilesIMS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot